A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)

NCT01650727 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

5

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

DRUG: Dinaciclib
BIOLOGICAL: Rituximab

Sponsor

Merck Sharp & Dohme LLC